MK-4214 (filgrastim biosimilar) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 1 Disease   1 Trial   1 Trial   4 News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-4214 (filgrastim biosimilar) / Merck (MSD)
2011-003399-36: A Phase III Randomized, Double-Blind, Active-Controlled Clinical Trial to Study the Efficacy and Safety of MK-4214 (filgrastim) and Neupogen™ as an Adjunct to Combination Chemotherapy with Doxorubicin and Docetaxel in Breast Cancer Patients

Ongoing
3
32
Europe
Filgrastim, Neupogen™, MK-4214, Neupogen™, Neupogen™
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Breast Cancer
 
 

Download Options